Complete UK Price Analysis: Mounjaro vs Wegovy Costs
Understanding the Price Difference Between Mounjaro and Wegovy in the UK Market
The price difference between Mounjaro and Wegovy reflects their distinct pharmaceutical profiles and manufacturing processes. Wegovy, containing semaglutide as a GLP-1 receptor agonist, follows Novo Nordisk's pricing structure with doses ranging from £79.99 for the 0.25mg starter pen to £209.99 for the 2.4mg maintenance dose. Mounjaro, formulated with tirzepatide as a dual GIP and GLP-1 receptor agonist by Eli Lilly, has established its own pricing framework reflecting the complexity of its dual-action mechanism. Both prescription-only medicines require clinical assessment through our GPhC-registered pharmacy (#9012878) to ensure appropriate prescribing.
When evaluating the price difference between Mounjaro and Wegovy, patients must consider the complete treatment journey rather than individual pen costs. Wegovy's five-dose escalation schedule (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg) provides a structured 17-week titration period, whilst Mounjaro follows its own dosing protocol. EverydayMeds offers both treatments with transparent pricing and discount codes applied at checkout - FIRST40 for new customers and DOSE25 for returning patients. The total investment varies depending on individual tolerance, efficacy response, and maintenance requirements determined during ongoing clinical monitoring.
Wegovy Pricing Structure and Bundle Value Analysis
Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance 2.4mg dose at £209.99. Our bundle options provide convenience for continuous treatment, including the Intro Duo (0.25mg & 0.5mg) for £169.99 and the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99. These prices reflect discount codes FIRST40 or DOSE25 applied at checkout, ensuring transparent pricing without hidden costs. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, offering treatment continuity for established patients.
Understanding the price difference between Mounjaro and Wegovy requires recognising that Wegovy's established market presence and extensive STEP trial programme influences its pricing strategy. The medication's proven cardiovascular benefits demonstrated in the SELECT trial, showing 20% reduction in major cardiovascular events, adds clinical value beyond weight management. Our bundle pricing eliminates the complexity of multiple orders, providing Reliable Supply continuity with single cold-chain delivery. Patients can compare both treatment costs during their clinical assessment, with prescribers offering guidance on cost-effectiveness based on individual clinical profiles.
Clinical Evidence Supporting Wegovy Investment Decisions
The STEP clinical trial programme provides robust evidence supporting Wegovy's efficacy profile, with patients achieving average weight loss of approximately 15% at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). STEP 5 demonstrated sustained weight loss of 15.2% at two years, indicating long-term treatment value. The SELECT cardiovascular outcomes trial showed 20% reduction in major adverse cardiovascular events, potentially offering additional health economic benefits beyond weight management.
When considering the price difference between Mounjaro and Wegovy, clinical evidence quality influences treatment value assessment. Wegovy's extensive real-world data from international markets provides confidence in treatment outcomes, whilst Mounjaro's SURMOUNT trials demonstrate the efficacy of dual GIP/GLP-1 receptor agonism. Both treatments require ongoing commitment, as STEP 1 extension data showed patients regained approximately two-thirds of weight lost within one year of discontinuation, emphasising the importance of sustained treatment investment.
Wegovy's GLP-1 Mechanism and Treatment Value
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone glucagon-like peptide-1. This mechanism reduces appetite by acting on brain appetite centres, promotes earlier satiety after meals, and may reduce food cravings by influencing reward pathways. The once-weekly injection via FlexTouch pen provides consistent therapeutic levels throughout the seven-day dosing interval. Unlike dual-action alternatives, Wegovy's single-pathway approach offers established safety profiles with over five years of semaglutide clinical experience. The medication works alongside lifestyle modifications, requiring commitment to reduced-calorie diet and increased physical activity for optimal outcomes.
Streamlined Online Ordering Process for Both Treatments
EverydayMeds simplifies the process of accessing both Wegovy and Mounjaro through our three-step online pathway. The clinical assessment takes approximately three minutes, covering medical history, current medications, weight management goals, and contraindication screening. Our qualified prescribers review applications within three working days (express 24-hour service available), ensuring appropriate treatment selection based on individual clinical profiles. Once approved, medications are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. Our GPhC-registered pharmacy (#9012878) ensures all medications are genuine manufacturer products with full traceability.
Storage Advantages and Practical Considerations
Understanding the price difference between Mounjaro and Wegovy includes practical storage considerations affecting treatment convenience. Wegovy offers superior storage flexibility, remaining stable at room temperature (below 30°C) for up to six weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature stability. This advantage proves valuable for travel, work situations, or temporary storage challenges. The FlexTouch pen design provides intuitive injection technique with automatic needle insertion and dose confirmation. Both treatments require refrigerated storage at 2-8°C before first use, but Wegovy's extended room temperature tolerance reduces storage-related treatment interruptions.
Comprehensive Treatment Cost Comparison for UK Patients
The price difference between Mounjaro and Wegovy extends beyond individual pen costs to encompass total treatment investment over time. Wegovy's escalation schedule requires five different dose strengths, with most patients reaching 2.4mg maintenance therapy by week 17. Our bundle options reduce ordering frequency whilst ensuring treatment continuity - the Elevate Trio (1mg, 1.7mg & 2.4mg) at £499.99 covers the final escalation phases. Mounjaro follows its own dose progression, with pricing reflecting the dual-receptor agonist complexity.
Long-term cost considerations include maintenance therapy duration, with both treatments requiring ongoing administration for sustained benefits. Our clinical team provides ongoing monitoring to optimise dose selection and treatment duration based on individual response patterns. The discount codes FIRST40 and DOSE25 apply to both treatment options, ensuring equitable access regardless of medication choice. Treatment costs may be offset by potential reductions in obesity-related healthcare expenses and improved quality of life outcomes demonstrated in clinical trials.
Expert Treatment Selection and Purchase Guidance
Choosing between Wegovy and Mounjaro based on price difference alone overlooks important clinical considerations that influence treatment success. Our prescribers evaluate BMI, weight-related comorbidities, previous weight management attempts, and individual tolerance factors when recommending treatment options. Both medications are available from EverydayMeds, allowing prescribers to select the most appropriate option based on clinical assessment rather than availability constraints. The online consultation process captures detailed medical history to ensure safe, effective treatment selection. Start your clinical assessment today at https://everydaymeds.co.uk/collections/wegovy to compare both treatment options with professional guidance. Our clinical team provides ongoing support throughout your weight management journey, with dose adjustments and treatment optimisation based on individual response patterns and tolerance profiles.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
